Viewing Study NCT07042204


Ignite Creation Date: 2025-12-24 @ 8:02 PM
Ignite Modification Date: 2025-12-31 @ 2:25 AM
Study NCT ID: NCT07042204
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-27
First Post: 2025-06-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects
Sponsor: Merna Nasser Mohamed Mostafa Ibrahim Elnahas
Organization:

Study Overview

Official Title: Effectiveness of Extended Platelet-Rich Fibrin (ePRF) Alone and in Combination With Bioactive Glass Nanoparticles in the Treatment of Grade II Furcation Defects
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.
Detailed Description: A total of 30 grade II furcation defects will be randomly divided into three groups as follows:

Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.

Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).

Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: